Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (688)
All Articles published online
|
Publishing Process of This Article
|
Nov 24, 2025 (publication date) through Mar 10, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Badroon NA, Alsalahi A, Aljaberi MA, Abdul Majid N, Alshawsh MA. Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications. World J Clin Oncol 2025; 16(11): 110911 [PMID: 41355908 DOI: 10.5306/wjco.v16.i11.110911] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Badroon NA, Alsalahi A, Aljaberi MA, Abdul Majid N, Alshawsh MA. Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications. World J Clin Oncol 2025; 16(11): 110911 [PMID: 41355908 DOI: 10.5306/wjco.v16.i11.110911] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v16/i11/110911.htm |
| Number | Citing Articles |
| 1 |
Yezi Xia, Yinwei Zhang, Ying Li, Xiaojing Li, Yaling Wu, Qi Yao. Cardamonin ameliorates neuroinflammation in Parkinson’s disease by regulating NF-κB signaling. Hereditas 2026; doi: 10.1186/s41065-026-00660-3
|